PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
Octapharma USA is offering Balfaxar (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex). The new non-activated four factor prothrombin complex concentrate (4F-PCC) ...
Pune, July 22, 2020 (GLOBE NEWSWIRE) -- The global prothrombin complex concentrate (PCC) market size is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6% during the forecast ...
Pune, Maharashtra, India, January 19 2021 (Wiredrelease) Prudour Pvt. Ltd –:Market.us, one of the worlds leading by prominent market research firms has released a new recent work on “Prothrombin ...
Rapid Warfarin Reversal With 4-Factor Prothrombin Clinical experience suggests that recently approved 4-factor prothrombin complex concentrate is superior to fresh frozen plasma in the management of ...
About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback